Gerresheimer Records Strong Revenue Growth in the 2012 Financial Year

Gerresheimer Records Strong Revenue Growth in the 2012 Financial Year 
DÜSSELDORF, Germany, Feb. 14, 2013 /CNW/ - 

    --  Revenues rise by 11.4% (9.8% at constant exchange rates) to EUR
    --  Adjusted operating margin (adjusted EBITDA margin) amounts to
    --  Net income grows by 22.2% to EUR 66.5m
    --  Proposed dividend of EUR 0.65 per share
    --  Presence in the emerging markets most recently expanded through
        two acquisitions in India

Gerresheimer AG, one of the leading worldwide partners of the pharma and 
healthcare industry, has closed the 2012 financial year with significant 
growth in revenues and profits. "We achieved all our targets in 2012. We 
recorded another year of strong growth in our business activities with the 
pharmaceutical sector, which once again proved to be relatively immune to 
cyclical effects. We are investing heavily in expanding our production 
capacity for medical devices such as prefilled glass syringes, insulin pens 
and inhalers. We are also focusing on the fast-growing emerging markets, 
especially in China, Brazil and India. In 2012 we succeeded in expanding our 
position in India in particular with the acquisition of two companies there," 
says Uwe Röhrhoff, CEO of Gerresheimer AG.

In the 2012 financial year (December 1, 2011 to November 30, 2012), 
Gerresheimer recorded substantial growth in revenues of 11.4%. Revenues rose 
to EUR 1,219.1m. At constant exchange rates, revenues increased by 9.8%. In 
particular Gerresheimer achieved strong growth in the pharma segment coupled 
with good revenue results in the cosmetic glass business and the life science 
research segment.

Gerresheimer increased its operating result (adjusted EBITDA) by 8.8% to EUR 
236.5m in the 2012 financial year. The adjusted EBITDA margin amounts to 
19.4%, compared to the prior year's 19.9%. Net income rose by 22.2% to EUR 
66.5m. Earnings per share rose by 19.3% to EUR 1.92. Adjusted earnings per 
share increased by 4.9% to EUR 2.56.

Gerresheimer invested EUR 118.9m in the 2012 financial year (up from EUR 86.2m 
in 2011). The company is expanding its production capacity for so-called 
medical devices, i.e. products for drug delivery such as prefilled glass 
syringes, insulin pens and asthma inhalers, in Germany, Czech Republic and 
elsewhere. The Company is also focusing on growth in the emerging markets. In 
April 2012 Gerresheimer acquired Neutral Glass, one of India's leading 
manufacturers of pharmaceutical vials. This was followed in December 2012 by 
the acquisition of the Indian company Triveni, the regional market leader for 
plastic pharmaceutical packaging and closures. Gerresheimer intends to achieve 
both organic growth and growth through acquisitions in the future.


Gerresheimer is expecting growth in revenues at constant exchange rates of 
five to six percent for the financial year 2013. The Company expects an 
adjusted EBITDA margin on prior year level (2012: 19.4%). Due to the good 
growth perspectives the investment volume of the financial year 2013 will be 
on the same level as the financial year just passed (2012: EUR 119m).

"2012 was a good year for Gerresheimer AG. As in the past, we want our 
shareholders to participate in the positive development of our business," said 
Uwe Röhrhoff. The Management and Supervisory Boards have agreed to propose a 
dividend of EUR 0.65 per share for the financial year 2012 at the Annual 
General Meeting on April 18, 2013. This represents a dividend ratio of 25% of 
adjusted net income. This year's dividends are payable tax-free to 
shareholders resident in Germany due to Gerresheimer AG's tax situation.

The online annual report is available at:

Jens Kürten Director Corporate Communication & Marketing Telephone: 
+49-211-6181-250 Fax: +49-211-6181-241 

SOURCE: Gerresheimer AG

To view this news release in HTML formatting, please use the following URL:

CO: Gerresheimer AG

-0- Feb/14/2013 07:17 GMT

Press spacebar to pause and continue. Press esc to stop.